Persistent visual impairment in multiple sclerosis: prevalence, mechanisms and resulting disability

2013 ◽  
Vol 19 (12) ◽  
pp. 1618-1626 ◽  
Author(s):  
Laurence Jasse ◽  
Sandra Vukusic ◽  
Françoise Durand-Dubief ◽  
Cristina Vartin ◽  
Carolina Piras ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Optic Neuropathy ◽  
Functional Disability ◽  
Life Questionnaire ◽  
Ocular Motor ◽  
Visual Disability ◽  
Motor Pathways ◽  
Related Data ◽  
High Prevalence ◽  
Related Quality

Objective: The objective of this article is to evaluate in multiple sclerosis (MS) patients the prevalence of persistent complaints of visual disturbances and the mechanisms and resulting functional disability of persistent visual complaints (PVCs). Methods: Firstly, the prevalence of PVCs was calculated in 303 MS patients. MS-related data of patients with or without PVCs were compared. Secondly, 70 patients with PVCs performed an extensive neuro-ophthalmologic assessment and a vision-related quality of life questionnaire, the National Eye Institute Visual Functionary Questionnaire (NEI-VFQ-25). Results: PVCs were reported in 105 MS patients (34.6%). Patients with PVCs had more frequently primary progressive MS (30.5% vs 13.6%) and more neuro-ophthalmologic relapses (1.97 vs 1.36) than patients without PVCs. In the mechanisms/disability study, an afferent visual and an ocular-motor pathways dysfunction were respectively diagnosed in 41 and 59 patients, mostly related to bilateral optic neuropathy and bilateral internuclear ophthalmoplegia. The NEI-VFQ 25 score was poor and significantly correlated with the number of impaired neuro-ophthalmologic tests. Conclusion: Our study emphasizes the high prevalence of PVC in MS patients. Regarding the nature of neuro-ophthalmologic deficit, our results suggest that persistent optic neuropathy, as part of the progressive evolution of the disease, is not rare. We also demonstrate that isolated ocular motor dysfunctions induce visual disability in daily life.

Improvement in Migraine-Specific Quality of Life in A Clinical Trial of Rizatriptan

Cephalalgia ◽  
1997 ◽  
Vol 17 (8) ◽  
pp. 867-872 ◽  
Author(s):  
NC Santanello ◽  
AB Polis ◽  
SL Hartmaier ◽  
MS Kramer ◽  
GA Block ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Trial ◽  
Functional Disability ◽  
Controlled Clinical Trial ◽  
Life Questionnaire ◽  
Test Statistic ◽  
Related Quality ◽  
Health Related ◽  
The Impact

A validated migraine-specific questionnaire (24-h Migraine Quality of Life Questionnaire1: 24-h MQoLQ) was used to assess the impact of migraine and migraine therapy on health related quality of life during an acute migraine attack. Male and female migraineurs aged 18-55 years were randomized to placebo ( n = 41), rizatriptan 2.5 mg ( n = 47), 5 mg ( n = 74), or 10 mg ( n = 85) in a triple-blind, placebo-controlled clinical trial. Rizatriptan 5 mg and 10 mg were significantly more efficacious than placebo on pain relief and functional disability. After accounting, for multiple comparisons to placebo, rizatriptan 10 mg showed significantly better responses compared to placebo on three of five domains of 24-h MQoLQ (social functioning, migraine symptoms, and feelings/concerns). The O'Brien's Rank Sum Test statistic showed a statistically significant overall difference on the 24-h MQoLQ between the 10 mg rizatriptan and placebo groups ( p = 0.005) and for the overall close trend ( p 0.001).

Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study

2011 ◽  
Vol 17 (11) ◽  
pp. 1341-1350 ◽  
Author(s):  
X Montalban ◽  
G Comi ◽  
P O’Connor ◽  
SM Gold ◽  
A de Vera ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Controlled Study ◽  
Life Questionnaire ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

Background: Health-related quality of life (HRQoL) worsens with multiple sclerosis (MS) relapses and disease progression. Common symptoms including depression and fatigue may contribute to poor HRQoL. Objectives: To report exploratory analyses assessing the impact of fingolimod (FTY720) on HRQoL and depression in a phase II study of relapsing MS. Methods: The Hamburg Quality of Life Questionnaire in MS (HAQUAMS) and Beck Depression Inventory second edition (BDI-II) scores were assessed during a 6-month, placebo-controlled study and optional extension. Results: HAQUAMS total score improved with fingolimod and worsened with placebo. Mean score change from baseline to month 6 was −0.02 with fingolimod 1.25 mg ( p < 0.05 versus placebo), −0.01 with fingolimod 5.0 mg and + 0.12 with placebo. Categorical data supported a clinically important effect of fingolimod on HRQoL. Fingolimod 1.25 mg was also beneficial over placebo in the fatigue/thinking HAQUAMS sub-domain ( p < 0.05 versus placebo). Change in mean BDI-II scores from baseline to month 6 and the proportion of patients with BDI-II scores indicative of clinical depression favored fingolimod 1.25 mg over placebo ( p < 0.05 for both). At month 4, mean BDI-II and HAQUAMS total scores appeared to be maintained in fingolimod-treated patients. Conclusion: Fingolimod 1.25 mg may improve HRQoL and depression at 6 onths compared with placebo in patients with relapsing MS.

scholarly journals Upper Limb Dexterity in Multiple Sclerosis Patients: An Important and Underrated Morbidity

2020 ◽  
pp. 0000-0000
Author(s):  
Ricardo N. Alonso ◽  
Maria B. Eizaguirre ◽  
Leila Cohen ◽  
Cecilia Quarracino ◽  
Berenice Silva ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Equation Modeling ◽  
Life Questionnaire ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Edss Score ◽  
Multiple Sclerosis Patients

Abstract Background: Scales to assess disability in multiple sclerosis (MS) rarely provides reliable data on the actual global impairment. Upper limbs (UL) dysfunction is usually overlooked, which has a negative impact on the patient's well-being. Objectives: 1) to analyze the association between UL dexterity, lower limbs (LL) speed and the EDSS score. 2) To analyze the difference in UL dexterity between patients with EDSS &lt;5 and ≥5. 3) To study the association that UL dexterity, LL speed and the EDSS score have with both health-related quality of life measurements and depression. Methods: Our sample included 140 adults with MS. They were evaluated using the Nine-Hole Peg Test, the Timed 25-Foot Walk test, the EDSS, the Multiple Sclerosis International Quality of Life questionnaire (MusiQol), and the Beck Depression Inventory. We conducted a thorough descriptive-analytical research using Spearman's correlation, multiple linear regression and structural equation modeling. Results: UL dexterity was more closely related to the EDSS than LL speed (r: 0.43 vs. 0.29, R2: 0.38). UL dexterity was greatest in patients with EDSS &lt;5 (P &lt; .001). Moreover, UL dexterity was negatively associated with EDSS and the MusiQol (rS: between −0.557 and −0.358, P &lt; .05). The correlation that depression has with loss of dexterity in UL was higher than the one it has with LL speed (0.098 vs 0.066, t &gt; 1.96). Conclusions: UL dexterity is associated and global disability, depression, and health-related quality of life. We advocate for the assessment of UL dexterity during MS patients' consultations to adopt a better approach to their functional impairment.

Multiple Sclerosis and Female Sexual Dysfunction: Impact of Disease Severity and Duration

2020 ◽  
pp. 33-37
Author(s):  
O.I. Nehrych ◽  
◽  
V.I. Pyrohova ◽  
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Sexual Dysfunction ◽  
Female Sexual Dysfunction ◽  
Sexual Life ◽  
Common Symptom ◽  
Life Questionnaire ◽  
Total Quality ◽  
Related Quality

Despite a lot of studies of sexual dysfunction there are still no consistent data about the prevalence and characteristics of sexual dysfunction among women with MS, especially it terms of multiple sclerosis severity and duration. The objective: was to determine the prevalence of various SD symptoms among female MS patients, depending on the age and severity of the disease, and evaluate SD impact on quality of life. Materials and methods. The study population includes 116 female patients with MS (McDonald’s criteria, 2010). Health – related quality of life was measured by the Multiple Sclerosis Quality of Life Questionnaire (MSQOL-54). Sexual dysfunction was assessed with the Sexual Function Index for Women with Multiple Sclerosis Questionnaire. Results. A direct average correlation between satisfaction with sexual life and relationships; sexual activity and arousal; discomfort and pain during sexual intercourse; direct impact of multiple sclerosis on sexual life and total quality of life, physical health component, mental health component was established (р<0.05). The prevalence of sexual dysfunction increases with the age and disease duration. Conclusions. Our data confirm that SD is common symptom in women with MS and significantly affect their quality of life. Key words: multiple sclerosis, female sexual dysfunction.

The functional index for living with multiple sclerosis: development and validation of a new quality of life questionnaire

2009 ◽  
Vol 15 (10) ◽  
pp. 1239-1249 ◽  
Author(s):  
JM Wesson ◽  
JA Cooper ◽  
LS Jehle ◽  
SN Lockhart ◽  
K. Draney ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Internal Consistency ◽  
Convergent Validity ◽  
Life Questionnaire ◽  
Health Related Quality ◽  
Functional Index ◽  
Related Quality ◽  
Health Related

Addressing health-related quality of life is considered a desirable component of routine care for patients with multiple sclerosis. However, use of available health-related quality of life surveys is not part of routine multiple sclerosis care, possibly due to administration, scoring, and interpretation challenges presented by available questionnaires. The 25-item Functional Index for Living with Multiple Sclerosis (FILMS) questionnaire was developed and validated to allow providers to monitor and easily apply health-related quality of life information to the patient encounter. The development and pilot test processes and the results of the validation study are reported here. Convergent validity, internal consistency reliability, and test—retest reproducibility were evaluated. Strong correlations of Functional Index for Living with Multiple Sclerosis subscales with control questionnaires were demonstrated by Pearson’s correlation coefficients from 0.73 to 0.88. Internal consistency reliabilities ranged from 0.80 to 0.90, demonstrating that items were grouped into the appropriate subscale domains and that the subscale domains and the questionnaire as a whole exhibited good directionality. Test—retest reproducibility was 0.91.

scholarly journals Reliability and acceptability of the Multiple Sclerosis Quality of Life-29 questionnaire in an English-speaking cohort

2018 ◽  
Vol 25 (11) ◽  
pp. 1539-1542
Author(s):  
Georgina Baker ◽  
Krishnan Padmakumari Sivaraman Nair ◽  
Kathleen Baster ◽  
Rosalba Rosato ◽  
Alessandra Solari
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Intraclass Correlation ◽  
Correlation Coefficients ◽  
Life Questionnaire ◽  
Good Test ◽  
Quality Of Life Questionnaire ◽  
Related Quality ◽  
English Speaking

Background: Multiple Sclerosis Quality-of-Life Questionnaire-54 (MSQoL-54) is a disease-specific instrument for assessing health-related quality of life (HRQoL). Due to the number of items, the time taken to complete it is long. A shorter 29-item version, Multiple Sclerosis Quality-of-Life Questionnaire-29 (MSQoL-29) is yet to be evaluated in English. Objective: To assess reliability and acceptability of English version of MSQoL-29. Methods: Among 100 participants with MS who first completed both MSQoL-54 and MSQoL-29, 91 completed MSQoL-29 after 4–8 weeks. We looked for internal consistency (Cronbach’s alpha), acceptability, reliability (intraclass correlation coefficients (ICCs)) and agreement (Bland–Altman plots). Results: ICCs were strongly positive between MSQoL-54 and MSQoL-29 (Physical Health Composite (PHC) –ICC = 0.914, confidence interval (CI) = 0.872–0.942; Mental Health Composite (MHC) – ICC = 0.875, CI = 0.814–0.916) and between the two MSQoL-29 (PHC – ICC = 0.970, CI = 0.955–0.980; MHC – ICC = 0.937, CI = 0.904–0.958). On Bland–Altman plots, the MSQoL-29 scores of 95% of participants during two visits were within the limits of agreement (LOAs). Time taken to complete MSQoL-29 was 7.2 ± 2.9 minutes and MSQoL-54 was 19.79 ± 5.4 minutes ( p = 0.0001). Conclusion: MSQoL-29 has good test–retest reliability in English-speaking population and was quicker to complete.

scholarly journals Impact of Visual Impairment on Health-Related Quality of Life in Multiple Sclerosis

2010 ◽  
Vol 12 (2) ◽  
pp. 83-91 ◽  
Author(s):  
Vivek S. Pawar ◽  
Gauri Pawar ◽  
Lesley-Ann Miller ◽  
Iftekhar Kalsekar ◽  
Jan Kavookjian ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Visual Impairment ◽  
Life Questionnaire ◽  
Health Related Quality ◽  
Patient Reported ◽  
Related Quality ◽  
Health Related ◽  
The Impact

The aim of this study was to evaluate the impact of visual impairment on health-related quality of life (HRQOL) in patients with multiple sclerosis (MS). Patients at an outpatient MS clinic were asked to complete a battery of patient-reported outcome questionnaires. Health-related quality of life was measured using the Hamburg Quality of Life Questionnaire for Multiple Sclerosis (HAQUAMS), while visual impairment was measured using the Visual Function Questionnaire (VFQ). Hierarchical regression was used to determine the relative contribution of visual impairment to HRQOL. Usable responses were obtained for 116 MS patients. Those with higher levels of visual impairment (lower scores on the VFQ) reported significantly lower HRQOL (β = –0.01, P = .0007). Visual impairment also explained an additional 4% variance in the HRQOL scores, independent of disability and depression (ΔR2 = 0.04, F7,108 = 36.58). Overall, disability was the strongest predictor of HRQOL, explaining over 60% of the variation in HRQOL scores. The model explained 70% of the total variance in HRQOL. Given the prevalence of visual impairment and its influence on overall HRQOL, MS patients should be routinely screened using standard ophthalmic examination procedures or self-administered questionnaires such as the VFQ.

A health-related quality of life questionnaire for multiple sclerosis Patients

2009 ◽  
Vol 100 (3) ◽  
pp. 148-155 ◽  
Author(s):  
L. E. M. A. Pfennings ◽  
H. M. Ploeg ◽  
L. Cohen ◽  
I. Bramsen ◽  
C. H. Polman ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Life Questionnaire ◽  
Health Related Quality ◽  
Quality Of Life Questionnaire ◽  
Related Quality ◽  
Health Related ◽  
Multiple Sclerosis Patients

scholarly journals Fatigue and depression in multiple sclerosis: Correlation with quality of life

2011 ◽  
Vol 63 (3) ◽  
pp. 617-622 ◽  
Author(s):  
Svetlana Miletic ◽  
Gordana Toncev ◽  
Jasna Jevdjic ◽  
B. Jovanovic ◽  
D. Canovic
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Clinical Manifestations ◽  
Life Questionnaire ◽  
Relapsing Remitting ◽  
Related Quality ◽  
Health Related ◽  
Fatigue Severity ◽  
Severity Of Depression

The aim of this work was to examine the relationship between fatigue and depression, common features of multiple sclerosis (MS), and the quality of life (QOL). The study was comprised of 120 patients with clinical manifestations of definite MS. Relapsing-remitting MS was present in 76.7% patients and secondary progressive MS was present in 23.3% patients. Mean disease duration was 8.1 ? 5.6 years and the mean Expanded Disability Status Score (EDSS) was 3.5 ? 1.8 (range 1-8). Fatigue was measured with the Fatigue Severity Scale (FSS), depression was measured by the Beck Depression Inventory (BDI) and QOL was assessed using the health-related quality of life questionnaire SF-36. We observed that the global FSS score was 4.6 ? 1.8 (range 1-7) and BDI was 10.7 ? 10.3 (range 0-39). The FSS significantly and positively correlated with the BDI scores (r = 0.572; p = 0.000). The severity of fatigue had a significant impact on the quality of life (r = -0.743; p = 0.000), in particular on mental health (r = -0.749; p = 0.000). We observed a significant correlation between the severity of depression and impaired quality of life (r = -0.684; p = 0.000). This study shows that fatigue and depression are associated with impaired QOL in MS.

Sign in / Sign up

Export Citation Format

Share Document